Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.